Sanofi is expanding its biosurgery business by acquiring Pluromed, a medical device company based in Massachusetts, USA.
With the acquisition, the French drugmaker is getting hold of LeGoo, which is described as a highly innovative US Food and Drug Administration-approved gel for temporary endovascular occlusion of blood vessels during surgical procedures. Financial details have not been disclosed.
Pluromed has developed a polymer technology, pioneering the use of injectable plugs "to improve the safety, efficacy and economics of medical interventions". Alison Lawton, head of the Sanofi Biosurgery unit, said LeGoo is a "breakthrough technology with the potential to change the paradigm of vascular and cardiovascular surgical procedures, by providing fast, temporary control of blood flow while avoiding vessel trauma associated with standard of care".
_Jean-Marie Vogel, Pluromed chief executive, said "the synergies between our companies were clear from the beginning,” adding that Sanofi "has the expertise and resources necessary to bring LeGoo to market and drive adoption".